Additionally, the 36-month beta value for SNDX is 0.90. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for SNDX is 81.08M and currently, short sellers hold a 26.29% ratio of that float. The average trading volume of SNDX on January 23, 2025 was 2.17M shares.
SNDX) stock’s latest price update
Syndax Pharmaceuticals Inc (NASDAQ: SNDX)’s stock price has dropped by -3.07 in relation to previous closing price of 14.00. Nevertheless, the company has seen a gain of 6.02% in its stock price over the last five trading days. prnewswire.com reported 2025-01-15 that – U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis – – Pivotal data from the AGAVE-201 trial supporting FDA approval show treatment with Niktimvo resulted in durable responses across all organs studied and patient subgroups – WILMINGTON, Del. and WALTHAM, Mass.
SNDX’s Market Performance
Syndax Pharmaceuticals Inc (SNDX) has experienced a 6.02% rise in stock performance for the past week, with a 5.60% rise in the past month, and a -30.52% drop in the past quarter. The volatility ratio for the week is 4.22%, and the volatility levels for the past 30 days are at 4.71% for SNDX. The simple moving average for the past 20 days is 1.96% for SNDX’s stock, with a -28.73% simple moving average for the past 200 days.
Analysts’ Opinion of SNDX
Many brokerage firms have already submitted their reports for SNDX stocks, with UBS repeating the rating for SNDX by listing it as a “Buy.” The predicted price for SNDX in the upcoming period, according to UBS is $37 based on the research report published on October 24, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see SNDX reach a price target of $37. The rating they have provided for SNDX stocks is “Buy” according to the report published on June 28th, 2024.
Scotiabank gave a rating of “Sector Perform” to SNDX, setting the target price at $23 in the report published on January 31st of the previous year.
SNDX Trading at -8.80% from the 50-Day Moving Average
After a stumble in the market that brought SNDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.45% of loss for the given period.
Volatility was left at 4.71%, however, over the last 30 days, the volatility rate increased by 4.22%, as shares surge +5.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.15% lower at present.
During the last 5 trading sessions, SNDX rose by +7.50%, which changed the moving average for the period of 200-days by -39.97% in comparison to the 20-day moving average, which settled at $13.32. In addition, Syndax Pharmaceuticals Inc saw 2.65% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SNDX starting from Goldan Keith A., who purchase 1,250 shares at the price of $20.03 back on Jun 14 ’24. After this action, Goldan Keith A. now owns 52,623 shares of Syndax Pharmaceuticals Inc, valued at $25,037 using the latest closing price.
Stock Fundamentals for SNDX
Current profitability levels for the company are sitting at:
- -19.43 for the present operating margin
- -1.7 for the gross margin
The net margin for Syndax Pharmaceuticals Inc stands at -17.96. The total capital return value is set at -0.88. Equity return is now at value -81.88, with -72.01 for asset returns.
Based on Syndax Pharmaceuticals Inc (SNDX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -303.12. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -1726.95.
Currently, EBITDA for the company is -229.94 million with net debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of 61.64. The receivables turnover for the company is 3.53for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.99.
Conclusion
In conclusion, Syndax Pharmaceuticals Inc (SNDX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
